Loading…
Elimination of Neglected Diseases Act of 2006
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,105 other S bills in the 109th — cohort avg 35d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2008 · fourth_quarter · Consumer Issues/Safety/Products
HR 780, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 2699, Neglected Diseases Elimination Act, promote R&D S 484, Enhancing Drug Safety and Innovation Act 2006 S 1082, FDA Revitalization Act 3/07 HR 2900, FDA Amendments Act 2007 S. 242, Pharmaceutical Market Access and Drug Safety Act 3/07 HR. 380, Pharmaceutical Market Access and Drug Safety Act 2/07
Client expense: $3,250,000 · Firm income: Not reported
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2008 · third_quarter · Consumer Issues/Safety/Products
HR 780, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 2699, Neglected Diseases Elimination Act, promote R&D S 484, Enhancing Drug Safety and Innovation Act 2006 S 1082, FDA Revitalization Act 3/07 HR 2900, FDA Amendments Act 2007 S. 242, Pharmaceutical Market Access and Drug Safety Act 3/07 HR. 380, Pharmaceutical Market Access and Drug Safety Act 2/07
Client expense: $3,070,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2008 · third_quarter · Consumer Issues/Safety/Products
HR 780, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 2699, Neglected Diseases Elimination Act, promote R&D S 484, Enhancing Drug Safety and Innovation Act 2006 S 1082, FDA Revitalization Act 3/07 HR 2900, FDA Amendments Act 2007 S. 242, Pharmaceutical Market Access and Drug Safety Act 3/07 HR. 380, Pharmaceutical Market Access and Drug Safety Act 2/07
Client expense: $3,060,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2008 · second_quarter · Consumer Issues/Safety/Products
HR 780, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 2699, Neglected Diseases Elimination Act, promote R&D S 484, Enhancing Drug Safety and Innovation Act 2006 S 1082, FDA Revitalization Act 3/07 HR 2900, FDA Amendments Act 2007 S. 242, Pharmaceutical Market Access and Drug Safety Act 3/07 HR. 380, Pharmaceutical Market Access and Drug Safety Act 2/07
Client expense: $3,060,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2008 · first_quarter · Consumer Issues/Safety/Products
HR 780, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 2699, Neglected Diseases Elimination Act, promote R&D S 484, Enhancing Drug Safety and Innovation Act 2006 S 1082, FDA Revitalization Act 3/07 HR 2900, FDA Amendments Act 2007 S. 242, Pharmaceutical Market Access and Drug Safety Act 3/07 HR. 380, Pharmaceutical Market Access and Drug Safety Act 2/07
Client expense: $2,800,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
2007 · mid_year · Consumer Issues/Safety/Products
HR 4157, Better Health Information System Act, health information technology HR 5975, Prescription Drug Effectiveness Act, drug prescriptions S 2699, Neglected Diseases Elimination Act, promote R&D S 484, Enhancing Drug Safety and Innovation Act S 1082, FDA Revitalization Act HR 2900, FDA Amendments Act HR 2300, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions HR 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation HR 5156, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting
Client expense: $7,220,000 · Firm income: Not reported
2006 · year_end · Consumer Issues/Safety/Products
HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 470, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety S 930, Food and Drug Administration Safety Act of 2005, drug safety HR 5156, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 3834, Online Pharmacy Consumer Protection Act of 2006, drug safety HR 2300, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions HR 4157, Better Health Information System Act, health information technology HR 5975, Prescription Drug Effectiveness Act, drug prescriptions S 2699, Neglected Diseases Elimination Act, promote R&D HR 2090, The Food and Drug Administration Improvement Act of 2005, drug safety HR 3196, The Fair Access to Clinical Trials ("RACT") Act of 2005, drug safety HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation, drug safety
Client expense: $5,800,000 · Firm income: Not reported
2006 · year_end · Consumer Issues/Safety/Products
HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 470, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety S 930, Food and Drug Administration Safety Act of 2005, drug safety HR 5156, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 3834, Online Pharmacy Consumer Protection Act of 2006, drug safety HR 2300, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions HR 4157, Better Health Information System Act, health information technology HR 5975, Prescription Drug Effectiveness Act, drug prescriptions S 2699, Neglected Diseases Elimination Act, promote R&D HR 2090, The Food and Drug Administration Improvement Act of 2005, drug safety HR 3196, The Fair Access to Clinical Trials ("RACT") Act of 2005, drug safety HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation, drug safety
Client expense: $7,720,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)